ARROWHEAD PHARMACEUTICALS, INC. Marketable Securities, Gain (Loss)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Marketable Securities, Gain (Loss) of $62.95 thousand for the 131-month period ending 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2014-11-25
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for the quarter ending 2012-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for the quarter ending 2012-06-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for the quarter ending 2011-12-31 was -$58.09K.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for fiscal 2012 was -$58.09K.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, gain (loss) for fiscal 2011 was -$261.22K.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 12 month | Marketable Securities, Gain (Loss) 98 month | Marketable Securities, Gain (Loss) 101 month | Marketable Securities, Gain (Loss) 104 month | Marketable Securities, Gain (Loss) 107 month | Marketable Securities, Gain (Loss) 110 month | Marketable Securities, Gain (Loss) 113 month | Marketable Securities, Gain (Loss) 116 month | Marketable Securities, Gain (Loss) 119 month | Marketable Securities, Gain (Loss) 122 month | Marketable Securities, Gain (Loss) 125 month | Marketable Securities, Gain (Loss) 128 month | Marketable Securities, Gain (Loss) 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $62.95K 10-Q · filed 2014-05-06 | |||||||||||||||
| 2013-12-31 | $62.95K 10-Q · filed 2014-02-04 | |||||||||||||||
| 2013-09-30 | $62.95K 10-K · filed 2013-12-18 | |||||||||||||||
| 2013-06-30 | $62.95K 10-Q · filed 2013-08-07 | |||||||||||||||
| 2013-03-31 | $62.95K 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | $62.95K 10-Q · filed 2013-02-13 | |||||||||||||||
| 2012-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | $0.00 derived: sum of 2 quarters · filed 2014-11-25 | $0.00 derived: sum of 3 quarters · filed 2014-11-25 | -$58.09K 10-K · filed 2014-11-25 | $62.95K 10-K · filed 2012-12-28 | |||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-07 | $0.00 derived: sum of 2 quarters · filed 2013-08-07 | -$58.09K 10-Q · filed 2013-08-07 | -$180.82K derived: sum of 4 quarters · filed 2013-08-07 | $62.95K 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-09 | -$58.09K 10-Q · filed 2013-05-09 | -$180.82K derived: sum of 3 quarters · filed 2013-05-09 | -$679.23K derived: sum of 4 quarters · filed 2013-05-09 | $62.95K 10-Q · filed 2012-05-08 | |||||||||||
| 2011-12-31 | -$58.09K 10-Q · filed 2013-02-13 | -$180.82K derived: sum of 2 quarters · filed 2013-02-13 | -$679.23K derived: sum of 3 quarters · filed 2013-02-13 | -$319.31K derived: sum of 4 quarters · filed 2013-02-13 | $62.95K 10-Q · filed 2012-02-09 | |||||||||||
| 2011-09-30 | -$122.73K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | -$621.14K derived: sum of 2 quarters · filed 2012-12-28 | -$261.22K derived: sum of 3 quarters · filed 2012-12-28 | -$261.22K 10-K · filed 2012-12-28 | $121.05K 10-K · filed 2011-12-20 | |||||||||||
| 2011-06-30 | -$498.41K 10-Q · filed 2012-08-13 | -$138.49K derived: sum of 2 quarters · filed 2012-08-13 | -$138.49K 10-Q · filed 2012-08-13 | $243.78K 10-Q · filed 2011-08-08 | ||||||||||||
| 2011-03-31 | $359.92K 10-Q · filed 2012-05-08 | $359.92K 10-Q · filed 2012-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |